{"id":191249,"date":"2026-10-23T15:00:15","date_gmt":"2026-10-23T15:00:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/191249\/"},"modified":"2026-10-23T15:00:15","modified_gmt":"2026-10-23T15:00:15","slug":"novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/191249\/","title":{"rendered":"Novo&#8217;s CagriSema helped women lose 25% of weight on average, analysis shows"},"content":{"rendered":"<p>Oct 20  \u2014  Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss \u200bon average in women with obesity or overweight, according to data analyzed after the completion of a late-stage study.<\/p>\n<p>CagriSema, viewed as a \u200csuccessor to the Danish drugmaker&#8217;s blockbuster weight-loss drug Wegovy, could help Novo claw back ground lost to \u2060rival Eli Lilly in the fast-growing \u200bweight-loss market. Wegovy faces patent expiries after \u20602030.<\/p>\n<p>Novo said a 2.4 milligram dose of CagriSema was associated with an \u200caverage weight loss of \u200c25% after 68 weeks in 2,309 women enrolled in a late-stage \u2060study called REDEFINE 1, compared with 3% \u2060weight loss in women on placebo. In the full trial of more than 3,400 adults, CagriSema had led to 22.7% weight loss, below the 25% Novo had targeted.<\/p>\n<p>The data on women participants was presented at the annual meeting of The Menopause Society in San Diego.<\/p>\n<p>CagriSema is \u200ca weekly injection combining cagrilintide, which mimics pancreatic \u200bhormone amylin, and semaglutide, the active ingredient in Wegovy.<\/p>\n<p>In a separate post hoc analysis, 1,902 overweight or obese women who received CagriSema 2.4 mg or placebo were evaluated by menopausal stage, Novo said.<\/p>\n<p>CagriSema was associated with clinically meaningful weight loss across all menopause stages by week 68, with an average weight loss of 26.7% in premenopausal women, 24.8% in \u200bperimenopausal women and 23.1% in postmenopausal women.<\/p>\n<p>&#8220;Many women with obesity or overweight experience weight \u200cgain as they \u200cmove through \u2060menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,&#8221; said Michelle Skinner Moore, vice president, medical affairs at Novo.<\/p>\n<p>Post hoc analyses are conducted after trials meet their primary goals. Novo said they were \u200chypothesis-generating and required further \u200bstudy.<\/p>\n<p>A US FDA decision on the approval \u200cof CagriSema for weight management is \u2060expected in \u200bthe fourth quarter of this year.<\/p>\n<p>(Reporting by Sneha S K in Bengaluru; Editing by \u200bJonathan Ananda)<\/p>\n","protected":false},"excerpt":{"rendered":"Oct 20 \u2014 Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss \u200bon&hellip;\n","protected":false},"author":2,"featured_media":191250,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1298,6402,6403,1343,33,38,272,6127,6404,135,2410,5423,6405,1646],"class_list":["post-191249","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-cars","tag-classifieds","tag-homes","tag-jobs","tag-local","tag-news","tag-novo-nordisk","tag-radio","tag-salt-lake","tag-sports","tag-television","tag-traffic","tag-utah","tag-weather"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117490825848970987","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/191249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=191249"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/191249\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/191250"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=191249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=191249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=191249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}